Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Gatherwright

Plastic and Reconstructive Surgery Cleveland, OH Medical Doctor

NPI 1437474566 CMS profile 2790710

2500 Metrohealth Dr, Cleveland, OH 44109

Open in the dashboard

General payments

$52,023

213 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Gatherwright of Cleveland, OH is reported in the CMS Open Payments database as having received $52,023 across 213 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,154 46
2024 General $1,509 22
2023 General $10,495 33
2022 General $4,387 34
2021 General $10,496 38
2020 General $2,187 8
2019 General $9,795 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Gatherwright
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to James Gatherwright were reported at $13,154. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year James Gatherwright Plastic and Reconstructive Surgery median Middle half National median
2019 $9,795 $335 $121–$1,264 $163
2020 $2,187 $162 $57–$417 $114
2021 $10,496 $245 $89–$735 $132
2022 $4,387 $325 $120–$932 $149
2023 $10,495 $343 $129–$999 $160
2024 $1,509 $390 $141–$1,085 $164
2025 $13,154 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Integra LifeSciences Corporation $20,305 79 payments
  2. Avita Medical Americas, LLC $11,689 15 payments
  3. AxoGen $9,626 23 payments
  4. AbbVie, Inc. $3,050 16 payments
  5. Musculoskeletal Transplant Foundation Inc. $2,300 3 payments
  6. Smith+Nephew, Inc. $681 14 payments
  7. RTI Surgical, Inc $503 3 payments
  8. Aroa Biosurgery Incorporated $483 12 payments
  9. PolyNovo North America LLC $477 4 payments
  10. Allergan Inc. $385 7 payments
  11. Other $2,525 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $27,450 10 payments
  2. Food and Beverage $14,950 190 payments
  3. Travel and Lodging $5,622 11 payments
  4. Honoraria $4,000 2 payments
Products named General payments · program years 2019–2025
  1. Recell $11,546 13 payments
  2. PRIMATRIX $10,856 48 payments
  3. INTEGRA WOUND MATRIX (THIN) $8,905 21 payments
  4. INTEGRA MESHED BILAYER WOUND MATRIX $8,905 21 payments
  5. Cohealyx $6,930 7 payments
  6. Permeaderm $6,930 7 payments
  7. SURGIMEND $4,726 6 payments
  8. CODMAN CERTAS $4,500 1 payment
  9. Integra $3,967 37 payments
  10. AXOGUARD NERVE PROTECTOR $3,476 15 payments
  11. Other $32,090 299 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

62

Median for Internal Medicine: 777

Drug cost

$189

Median for Internal Medicine: $73,373

Branded share of claims

25.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 32 $120
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 16 $42
Cephalexin Generic 14 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$49,357

Medicare's payments for the services billed

Medicare patients

57

Average age 73

Services billed

512

40 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 56%
Depression 37%
Diabetes 33%
Chronic kidney disease 30%
Cancer 26%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record